Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma 2018
2017 DNA topoisomerase-targeting chemotherapeutics: what’s new? 2017
2016 Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin 2016
2016 Tyrosyl-DNA Phosphodiesterase I a critical survival factor for neuronal development and homeostasis. 2016
2015 ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin 2015
2015 Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage 2015
2014 Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target 2014
2012 Erratum: Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: A member of the phospholipase D superfamily (Journal of Molecular Biology (2012) 415:4 (741-758)) 2012
2012 Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: A member of the phospholipase D superfamily 2012
2007 Mutation of a Conserved Active Site Residue Converts Tyrosyl-DNA Phosphodiesterase I into a DNA Topoisomerase I-dependent Poison 2007
2007 Structure of a SUMO-binding-motif Mimic Bound to Smt3p-Ubc9p: Conservation of a Non-covalent Ubiquitin-like Protein-E2 Complex as a Platform for Selective Interactions within a SUMO Pathway 2007
2006 Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress 2006
2005 Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage 2005
2004 Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin 2004
2004 Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines 2004
2004 Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons 2004
2003 In vitro pharmacokinetic study of the novel anticancer agent E7070: Red blood cell and plasma protein binding in human blood 2003
2003 DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin 2003
2002 Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study 2002
2002 DNA-based drug interactions of cisplatin 2002
2001 Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918 2001
1999 32P-postlabeling assay for the quantification of the major platinum- DNA adducts 1999
1999 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line 1999
1998 Effects of c-MYC oncogene modulation on differentiation of human small cell lung carcinoma cell lines 1998
1998 Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines. 1998
1997 Effects of an inducible anti-sense c-myc gene transfer in a drug- resistant human small-cell-lung-carcinoma cell line 1997
1997 Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line. 1997
1996 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines 1996
1996 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. 1996

Chapter

Year Title Altmetric
2015 The ubiquitin/proteasome pathway in neoplasia.  473-480. 2015

Full Name

  • Robert van Waardenburg